Heart Failure Policy Summit 2022
Virtual sessions took place on 26 October, 2 November, 9 November and 16 November 2022.
Find out more
From guidelines to action
This project aims to help the heart failure community advocate for change to close the gap between clinical guidelines and the reality of care for people living with heart failure.
Find out more
Spotlight series
The Spotlight series features evidence-based reports on topics at the forefront of debates about the future of heart failure care.
Find out more
heart graphic

Helping advance meaningful policy change on heart failure

The Heart Failure Policy Network is an independent, multidisciplinary platform of healthcare professionals, advocacy groups and policymakers from across Europe.

We aim to raise awareness of the unmet needs surrounding heart failure and its care, and to help drive meaningful changes in policy and practice.

Find out more
Latest
It is time to put quality of life at the centre of heart failure care
15 November 2022

More than 90% of people with heart failure would like regular discussion about quality of life to be part of their care, but this only happens for 20%.

Read article
Latest
The Heart Failure Policy Summit will put people with heart failure at the centre of global health policy debates
27 September 2022

The Heart Failure Policy Summit will offer an opportunity for heart failure advocates to build alliances across disease areas and link to broader health policy agendas.

Read article
Latest
How can heart failure advocates in Spain seize current opportunities to improve care?
22 September 2022

Our latest policy brief attempts to answer this question, examining existing opportunities and mechanisms to advocate for guideline-recommended care in Spain.

Read article
heart failure graphic
What is heart failure?

Affecting at least 15 million adults in Europe, heart failure is a common but complex clinical syndrome that occurs when the heart is unable to pump enough blood to meet body’s needs.

Its prevalence is expected to rise due to population ageing and improved survival rates for other long-term conditions, including cardiovascular diseases.

Find out more
The Heart Failure Policy Network is made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim, Roche Diagnostics and Bayer AG. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.